Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.

ABSTRACT:

Background

Oral anticoagulants (OACs) mitigate the risk of stroke in atrial fibrillation (AF) patients.

Objective

Elderly AF patients who were treated with OACs (apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin) were compared against AF patients who were not treated with OACs with respect to their clinical and economic outcomes.

Methods

Newly diagnosed AF patients were identified between January 2013 and December 2017 in the Medicare database. Evidence of an OAC treatment claim on or after the first AF diagnosis was used to classify patients into treatment-defined cohorts, and these cohorts were further stratified based on the initial OAC prescribed. The risks of stroke/systemic embolism (SE), major bleeding (MB), and death were analyzed using inverse probabil

SUBMITTER: Munir MB 

PROVIDER: S-EPMC8853505 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature